Liver Cancer Clinical Trials
Hepatobiliary Cancer
Learn More About Liver Cancer
For general information on liver cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| DCSZ11-101 | Hepatobiliary Cancer | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| A001 | Hepatobiliary Cancer | A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies | Immunotherapy | CDH17 targeting IO. | Closed | Arbele Pty Ltd | NCT05411133 | Enquire Now |
| GRWD5769-ST-01 | Hepatobiliary Cancer | A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies | Immunotherapy | Novel EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1). | Open - Recruiting | Grey Wolf Therapeutics Pty Ltd | NCT06923761 | Enquire Now |
| SR-8541A-001 | Hepatobiliary Cancer | Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors | Targeted | ENPP1 inhibitor | Open - Recruiting | Stingray Therapeutics | NCT06063681 | Enquire Now |
| SSGJ-709-101 | Hepatobiliary Cancer | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490 | Enquire Now |